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Minimal Hepatic encephalopathy: 
Effect of H. pylori infection 
and small intestinal bacterial 
overgrowth treatment on clinical 
outcomes
Shahab Abid1 ✉, Muhammad Kamran1, Adeel Abid2, nazish Butt  1, Safia Awan3 & 
Zaigham Abbas1
The effect Helicobacter pylori (Hp) infection and small intestinal bacterial over growth (SIBO) in minimal 
hepatic encephalopathy (MHE) is not well understood. The aim of the study was to determine the effect 
of eradication of Hp infection and SIBO treatment on MHE in patients with cirrhosis. Patients with 
cirrhosis were enrolled and MHE was determined by psychometric tests and critical flicker frequency 
analysis. Hp infection and SIBO were assessed by urea breath and Hydrogen breath tests respectively 
in patients with cirrhosis and in healthy volunteers. Patients with Hp infection and SIBO were given 
appropriate treatment. At six weeks follow-up, presence of Hp infection, SIBO and MHE status was 
reassessed. Ninety patients with cirrhosis and equal number of healthy controls were included. 55 
(61.1%) patients in the cirrhotic group were diagnosed to have underlying MHE. Among cirrhotic group, 
Hp infection was present in 28 with MHE (50.9%) vs. in 15 without MHE (42.8%) (p = 0.45). Similarly, 
SIBO was present in 17 (30.9%) vs. 11 (31.4%) (p = 0.95) in patients with and without MHE respectively. 
In comparison with healthy controls, patients with cirrhosis were more frequently harboring Hp and 
SIBO (47.7% vs. 17.7% (p < 0.001) and 31.1% vs. 4.4% (p < 0.001) respectively. On follow-up, all 
patients showed evidence of eradication of Hp and SIBO infection. Treatment of SIBO significantly 
improved the state of MHE in cirrhotics, however eradication of Hp infection did not improve MHE 
significantly. Additionally, patients with low Model for End-Stage Liver Disease (MELD) score and 
belonging to Child class B had significantly better improvement in MHE. A large number of patients with 
cirrhosis had either active Hp infection or SIBO with or without MHE, compared to healthy controls. 
Treatment of SIBO significantly improved MHE in patients with cirrhosis, whereas eradication of Hp did 
not affect the outcome of MHE in these patients.
Hepatic encephalopathy (HE) is a frequent complication of chronic liver disease (CLD)1. HE can be precipi-
tated by various factors like gastrointestinal bleeding, sepsis, azotemia, drugs (e.g. sedatives, diuretics), electrolyte 
imbalance and constipation. The most relevant substance considered in the pathogenesis of HE is ammonia, 
although the exact mechanisms of its neurotoxic effects are still under study2.
A substantial number of patients with advanced CLD have minimal hepatic encephalopathy (MHE), which 
is the earliest stage in the spectrum of HE. One study reported the occurrence of MHE to be as high as 50%in 
patients with CLD3. MHE, by definition, has no obvious clinical manifestations and is characterized by neuro-
cognitive impairment in attention, vigilance and integrative function4. It develops in patients with significant 
liver function impairment or with porto-systemic shunting. MHE is associated not only with impaired daily 
functioning and quality of life, but is also considered as an occupational and public health hazard i.e. patient 
may be unfit to drive a car, operate a machinery, handle finances etc.5. However, current practice guidelines do 
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not recommend treating MHE routinely6. MHE is not noticeable on clinical examination, but can be detected 
by various neuropsychological evaluations like Psychometric Hepatic Encephalopathy Score (PHES) and neuro-
physiological tests such as electro-encephalogram (EEG), spectral EEG, Critical Flicker Frequency (CFF), evoked 
potentials and computerized tests.
Various studies elucidating the relationship between active Helicobacter pylori (Hp) infection and hepatic 
encephalopathy have been published1,7. However, scanty data is available with regards to the same in MHE8.
Work done by Schulz and his colleagues in a prospective clinical trial (though without healthy control group for 
comparison) failed to show an increased prevalence of Hp infection in patients presenting with MHE as opposed 
to those without MHE9. In addition to this, much interest has recently developed to define the role of small intes-
tinal bacterial overgrowth (SIBO) among patients with MHE10,11. However, evidence of such a role in our patient 
population still seems to be lacking.
H. pylori are non-invasive, gram-negative bacteria recognized as a pathogen of upper gastrointestinal diseases, 
such as acute and chronic gastritis, gastro-duodenal ulcers and mucosa-associated lymphoid tissue (MALT) lym-
phoma. Additionally, H. pylori has also been characterized as group 1 (definitive) carcinogen by the International 
Agency for Research on Cancer (IARC) because of its association with gastric adenocarcinoma12. Studies on ani-
mal models have shown a significant increase in the liver fibrotic score and aminotransferase activity (and hence 
promote the development of CLD) in a group inoculated with Hp and CCl4 (carbon tetrachloride) compared with 
a CCl4treated group13. Moreover, by producing large amounts of highly active enzyme urease, Hp can convert 
urea to ammonia. This phenomenon results in alteration of neurotransmission, and hence affects consciousness 
and behavior, which has been implicated in causation of HE in patients with liver cirrhosis1.
SIBO is described as a proliferation of the bacterial population in the small intestine, particularly distal gut. 
CLD is associated with reduced gut motility and decreased gastric acid secretion in the stomach, resulting in 
gastric enteropathy. Both these factors can predispose to development of SIBO14. In addition, SIBO may facilitate 
translocation of bacteria or bacterial components (antigens) across the intestinal barrier, with harmful conse-
quences to health, one of which could be HE15.
The aim of our study was to determine whether treatment of active Hp infection and SIBO play a role in 
improving MHE in cirrhotic patients.
Methods
Study design. This was a prospective cohort study.
Setting. The study was conducted in the outpatient department of the Aga Khan University Hospital, Karachi, 
Pakistan.
Sample size. It is estimated that about 55% of patients with cirrhosis would have MHE based on a positive 
result for both Psychometric Hepatic Encephalopathy Scoring (PHES) and Critical Flicker Frequency (CFF) anal-
ysis16. Assuming the CFF to have a sensitivity of 87% and specificity of 82% for MHE, and a confidence interval of 
5%, the estimated sample size for this study was calculated to be 16417. To achieve the study objectives, the sample 
size was inflated by 10% to 180.
Sampling technique. Non-probability convenient sampling was used to identify the subjects.
Patients selection. Inclusion criteria. Patients with liver cirrhosis (irrespective of cause), 18 years and 
above, and without prior history of overt hepatic encephalopathy were included in the study.
Exclusion criteria. Patients currently receiving Hp eradication therapy, those on antibiotics for spontaneous 
bacterial peritonitis (SBP) prophylaxis or any other infection within last 4 weeks, or those who were on sedatives, 
rifaximin and/or lactulose (within 1 week) were excluded. Patients who had overt encephalopathy, severe cardiac, 
pulmonary, renal or cerebral disease, as well as those who had a history of recent upper gastrointestinal (GI) bleed 
(in last 6 weeks) were excluded from the study.
Ethical clearance. Ethical approval was obtained from the Ethical Review Committee (ERC) of the Aga 
Khan University, Karachi, Pakistan (ERC Reference #: 2873-Med-ERC-13). Written informed consent was 
obtained from all participants. Patients’ identification remained anonymous throughout the study. Patients were 
informed that the data will be used for research purpose and publication without revealing individual identifica-
tion and information. Study was performed in accordance with the principles of good clinical practice from the 
Declaration of Helsinki.
Data collection procedure. All patients already diagnosed to have cirrhosis based on clinical signs and 
symptoms, laboratory parameters and imaging studies, meeting the inclusion criteria and agreeing to participate, 
were enrolled after written informed consent. The informed consent was translated in Urdu (native) language as 
well. Child Turcotte Pugh (CTP) and Model of End-stage Liver Disease (MELD) scores of individual patients were 
calculated in order to determine disease severity. These patients then underwent psychometric hepatic enceph-
alopathy scoring (PHES) and critical flicker frequency (CFF) analysis to detect MHE. For the study purpose, a 
patient was diagnosed as having MHE if he tested positive for both CFF analysis and PHES testing. CFF analysis 
was incorporated as the examination is reliable, simple, easy to apply and can be performed without difficulty by 
patients with low educational background, such as patients from a country with relatively low levels of literacy.
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Diagnosis of MHE. Psychometric hepatic encephalopathy scoring (PHES). PHES is a battery of neuropsy-
chological tests which has long been regarded as a ‘gold standard’ for the assessment of MHE18,19. Patients were 
classified as having MHE when the PHES score was less than −4 points. PHES comprises of five components:4
Number connection test A. The patient was instructed to join numbered circles in order on a piece of paper. The 
time required to complete the task was scored.
Number connection test B. The patient was instructed to join numbered circles and alphabets e.g. 1, A, 2, B and 
so on.
Line tracing (trail drawing test). The patient was asked to trace a path, 5 mm wide, as fast as possible without 
touching the borders.
Serial dotting test. The patient was asked to dot the center of circles on a piece of paper.
Digit symbol test. The patient was asked to learn a code in which a digit is represented by a symbol. He/she then 
had to reproduce the symbol corresponding to the digit.
For calculation of PHES, individuals are supposed to complete all five components.
Critical flicker frequency (CFF) testing. The neurophysiologic CFF analysis is a tool that measures the 
ability of the central nervous system to detect flickering light, which is directly influenced by cortical activity5,20,21. 
In this method, an intermittent light stimulus appears as a flicker which is dependent on the frequency of light 
pulse presentation. The rate at which flicker just disappears is termed the critical flicker frequency (CFF). Patients 
were provided a CFF analyzer (a pair of spectacles shielding against outside light), and they were asked to concen-
trate on a red light, which was initially flickering. The frequency of the light was then gradually decreased by the 
operator until the patients perceived it as flickering, and they had to press a handgrip button when this happened. 
A lower level of 38 Hz was used as a cut-off for impaired CFF (and hence positive MHE).
Diagnosis of active H. pylori infection and SIBO. Diagnosis of active H. pylori infection was made by 
urea breath test (UBT) using Carbon 1322. Patients were asked to swallow 50 mg capsule of 13 C-urea. Breath 
samples were collected by exhaling into a 200 ml gas storage bag to be analyzed by an infrared spectrometer, and 
this was performed before and 15 minutes after the consumption of capsule. For the diagnosis of SIBO, hydrogen 
breath test (HBT) was utilized, in which 50 gram of lactulose was given to the subject, and an increase of ≥20 
parts per million (p.p.m) in hydrogen production at 90 min from base-line was taken as a positive diagnosis for 
SIBO.
Treatment of active H. pylori infection and SIBO. In our study, all patients were subjected to UBT and 
HBT. Patients who were tested positive were given appropriate therapy. Triple medicine regimen which includes 
clarithromycin, amoxicillin (for 10 days) and a proton pump inhibitor (for another 4 weeks) was given for the 
eradication of H. pylori infection23. We chose the triple regime as it is easier to administer and because low recur-
rence rates of H. pylori infection (despite considerable resistance rates of approximately 36%) have been reported 
from our part of the world24.
With regards to treatment of patients with SIBO, rifaximin 1200 mg/day for 1 week, which has shown good 
efficacy for SIBO in various studies, was administered25,26. This dosage was selected as there had been substan-
tial variation in the dose and duration of rifaximin at the time this study was conducted27. UBT and HBT were 
repeated after 6 weeks of completion of therapy28. CFF analysis and PHES were also repeated at the same time (i.e. 
after 6 weeks of completion of triple therapy and SIBO treatment) to detect an improvement in MHE. Rifaxamin 
was given to patients who came out as SIBO positive. Of note, none of the patients were given rifaximin as proph-
ylaxis for hepatic encephalopathy during the follow-up period.
For comparison with healthy subjects, 90 age and gender-matched controls (e.g. patients’ relatives, healthy 
hospital employees, etc.) were also enrolled in the study after written informed consent and underwent UBT and 
HBT. Those who were found positive for Hp and SIBO were treated accordingly (Fig. 1).
Statistical analysis. Data analysis was done using IBM SPSS Statistics for Windows, version 19.0 (Armonk, 
NY: IBM Corp. IBM Corp. Released 2011). Initially, the frequency was generated for all the variables. Continuous 
variables were presented as mean ± SD and categorical variables were presented as a percentage. Continuous 
variables between groups were compared by using unpaired t test or Mann Whitney test where appropriate. 
Categorical variables were compared by using the chi-square test or Fisher exact test. A p-value <0.05 was con-
sidered significant.
Results
A total of 90 patients were included in the study. Mean age was 44.9 ± 11.6 years, and the majority were males 
(53.3%). The clinical and laboratory parameters of cirrhotic patients with and without MHE are shown in Table 1.
Out of 90 cirrhotic patients, 55 (61.1%) were diagnosed to have underlying MHE based on a positive CFF 
analysis and PHES. Patients with MHE had a significantly higher CTP score than those without MHE (p = 0.02). 
Among patients who had MHE, 28 (50.9%) were positive for UBT (representing active Hp infection) as opposed 
to 15 (42.8%) in the non-MHE group (p = 0.45). Similarly, in the MHE group, 17 (30.9%) patients were diagnosed 
to have SIBO (based on a positive HBT), while 11 (31.4%) were SIBO positive in the non-MHE group (p = 0.95).
In comparison with healthy controls, overall, 43/90 (47.7%) patients with cirrhosis were positive on UBT as 
compared to 16/90 (17.7%) in age and gender-matched controls (p < 0.001). Likewise, there were 28/90 (31.1%) 
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patients with cirrhosis who were positive on HBT, as opposed to only 4/90 (4.4%) positive among controls 
(p < 0.001) (Table 2).
All subjects received appropriate therapy for active Hp and SIBO (as mentioned earlier). Six weeks after 
therapy, UBT and HBT were repeated in all patients irrespective of their baseline status, and interestingly those 
individuals who initially tested positive on either UBT and/ or HBT were now found to be negative on repeat 
Figure 1. Study Methodology- Flowchart. HP: Helicobacter pylori. SIBO: Small Intestinal Bacterial 
Overgrowth. MHE: Minimal Hepatic Encephalopathy.
With 
MHEn = 55 (%)
Without 
MHEn = 35 (%)
Age (years) 44.6 ± 11.9 45.5 ± 11.8
Gender
   Male 29(52.7) 19(54.3)
   Female 26(47.3) 16(45.7)
Ascites
   None 35(63.6) 26(74.3)
   Mild to Moderate 19(34.5) 9(25.7)
   Severe 1(1.8) 0
Concomitant HCCµ 4(7.3) 0
Hemoglobin (g/dl) 10.3 ± 1.6 10.1 ± 1.7
Platelets (x10E9/L) 92.6 ± 34 103.7 ± 38.1
Total Bilirubin (mg/dl) 2.6 ± 0.66 2.5 ± 0.78
Direct Bilirubin (mg/dl) 1.5 ± 0.53 1.4 ± 0.61
Indirect Bilirubin (mg/dl) 1.1 ± 0.44 1.04 ± 0.46
Albumin (g/dl) 2.7 ± 0.32 2.8 ± 0.39
Prothrombin time (sec) 15.4 ± 3.0 15.4 ± 2.5
INR∞ 1.4 ± 0.28 1.3 ± 0.25
Creatinine (mg/dl) 1.05 ± 0.22 1.02 ± 0.22
CTPα score 8.5 ± 0.99 8.05 ± 0.83*
MELDβ score 14.4 ± 3.06 13.8 ± 3.1
Table 1. Characteristics of patients with or without MHEΩ. *p < 0.05. ΩMHE: Minimal Hepatic 
Encephalopathy. µHCC: hepatocellular carcinoma, ∞INR: International normalization ratio. αCTP: Child-
Turcotte-Pugh, βMELD: Model for End-Stage Liver Disease.
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testing, indicating complete eradication of both the conditions. Seven cirrhotic patients who had underlying 
MHE remained positive for it even after treatment with anti-Hp therapy and/ or rifaximin. Among such patients, 
6 had active Hp infection, whereas 1 patient had SIBO. Six of the 12 individual patients with MHE, who did not 
have either active Hp infection or SIBO, were still found to have MHE at 6 weeks follow-up testing.
The overall improvement in MHE among patients who initially had SIBO versus those who did not have 
SIBO was found to be statistically significant. However, MHE among patients who had Hp infection did not 
show any significant improvement in their MHE. Furthermore, the improvement in the level of MHE was more 
prominent in patients with relatively less advanced liver disease i.e. those with lower MELD score and belonging 
to Child-Turcotte-Pugh (CTP) class B (Table 3).
Discussion
It is a well-known fact that SIBO is common in patients with liver cirrhosis29, which most likely occurs as a result 
of delayed small bowel transit in such individuals. Our study elucidated a significant improvement in the state of 
MHE in cirrhotic patients after treatment with SIBO therapy compared to those who had MHE without SIBO. 
Similar observations were also noted in a previously published study in which 26 out of 60 patients with cirrho-
sis who had MHE were treated by rifixamin for one week and found a significant improvement in MHE after 
treatment10.
On the other hand, we could not extrapolate the same results of improvement in MHE with regards to those 
patients with MHE who had Hp infection compared to those who have no Hp infection. Effect of Hp infection 
eradication over MHE in patients with cirrhosis remained debatable and earlier studies have also demonstrated 
controversial results; one such study has shown that anti-Hp therapy results in reducing ammonia levels in blood 
and hence improvement in MHE8. On the contrary, another study showed that Hp eradication does not induce 
any improvement in the psychometric and/or electrophysiological tests, which are used to diagnose MHE30. One 
plausible explanation for the above phenomenon is the fact that PPI use (given as part of Hp eradication regimen) 
has itself been linked to development of MHE, by inducing changes in the gut flora and subsequently leading to 
increased ammonia production31. We also use PPI in our study for an extended period of 4 week after triple ther-
apy. Therefore beneficial effect of eradication of Hp infection over MHE in present study is not evident hence we 
do not suggest treatment and eradication of Hp solely for improvement in MHE.
Our study showed that the frequency of Hp and SIBO was considerably higher in cirrhotic patients as com-
pared to the healthy controls. This observation has been elucidated by previous studies as well32,33. An Italian 
study34 demonstrated Hp antibodies to be positive in 89% of cirrhotic patients as compared to 59% controls 
(p < 0.0001). Later, in another study it was discovered that Hp infection along with an elevated transforming 
growth factor- β1 (TGF-β1) may accelerate hepatic fibrosis through increased TGF-β1-induced pro-inflammatory 
signaling pathways in hepatic stellate cells35. A recent study also found Hp infection to be more frequent among 
patients with cirrhosis secondary to chronic viral hepatitis, which happens to be the most prevalent cause of cir-
rhosis in our part of the world36. However, the cause and effect relationship between Hp infection and cirrhosis 
is still a matter of dispute.
Our study had a few limitations. Firstly, we did not measure serum ammonia levels of the subjects, as was 
performed in earlier similarly conducted studies on MHE16. However, as previous work has shown that arterial 
ammonia does not seem to play a major role in the diagnosis of MHE, we think that performing this test will not 
contribute substantial information37. The diagnosis of SIBO in our patients was not based on jejunal aspiration 
Healthy 
Controlsn = 90
Patients with liver cirrhosis
MHE∞ present 
Patientsn = 55
MHE absent 
Patientsn = 35 p value
SIBO present 4 (4.4) 17 (30.9) 11 (31.4) <0.001
SIBO absent 86 (95.6) 38 (69.1) 24 (68.6)
Hp infection present 16 (17.7) 28 (50.9) 15 (42.9) <0.001
Hp infection absent 74 (93.3) 27 (49.1) 20 (57.1)
Table 2. Frequency of active Hp* infection and SIBOΩ in patients and controls. *Hp: Helicobacter pylori ΩSIBO: 
Small Intestinal Bacterial Overgrowth ∞MHE: Minimal Hepatic Encephalopathy.
Cirrhotic patients 
with MHE n = 55
MHE 
improved
MHE not 
improved p value
SIBO positive 16 (38.1) 1 (7.7) 0.03
SIBO negative 26 (61.9) 12 (92.3)
Hp positive 22 (52.4) 6 (46.2) 0.69
Hp negative 20 (47.6) 7 (53.8)
Meld score 14.02 ± 2.80 16.0 ± 3.46 0.04
CTP classBC 40 (95.2) 2(4.8) 8 (61.5) 5 (38.5) 0.001
Table 3. Outcome of MHE∞ after six weeks of treatment of active Hp* infection and SIBOΩ.. ∞MHE: Minimal 
Hepatic Encephalopathy *Hp: Helicobacter pylori πSIBO: Small Intestine Bacterial Overgrowth.
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and culture, which is considered the gold standard. This method is invasive, as it requires small bowel intubation 
and laboratory skills in isolating anaerobes. Therefore, the inexpensive and non-invasive HBT has been utilized 
as has been done previously38 as a sole diagnostic tool for SIBO.
conclusion
Compared to healthy controls a significantly large number of cirrhotic patients had either active Hp infection or 
SIBO. Treatment of SIBO improves MHE in patients with cirrhosis, while eradication of Hp infection was not 
associated with improvement in MHE. Moreover, significant improvement in MHE was evident in patients with 
low MELD scores and belonging to CTP class B as compared to those with higher MELD scores and CTP class 
C respectively.
We suggest to treat SIBO in cirrhotic patients with MHE, however Hp eradication is not beneficial in such 
patients.
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